Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
CC transcript
Asset disposition
Cert. of designation
Director departure
Appointed director
ALIMERA SCIENCES INC (ALIM) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/04/2023 4 Morgan Adam (10% Owner) has filed a Form 4 on ALIMERA SCIENCES INC
Txns: Granted 50,000 options to buy @ $2.99, valued at $149.5k
10/04/2023 4 DeMont Ross D (Director) has filed a Form 4 on ALIMERA SCIENCES INC
Txns: Granted 50,000 options to buy @ $2.99, valued at $149.5k
10/04/2023 4 Parsons Erin (Director) has filed a Form 4 on ALIMERA SCIENCES INC
Txns: Granted 50,000 options to buy @ $2.99, valued at $149.5k
10/04/2023 4 Pizzo Peter J. III (Director) has filed a Form 4 on ALIMERA SCIENCES INC
Txns: Granted 50,000 options to buy @ $2.99, valued at $149.5k
10/04/2023 4 Werner Jason M. (COO) has filed a Form 4 on ALIMERA SCIENCES INC
Txns: Granted 225,000 shares @ $0
Granted 225,000 options to buy @ $2.99, valued at $672.8k
10/04/2023 4 Snisarenko John (Director) has filed a Form 4 on ALIMERA SCIENCES INC
Txns: Granted 50,000 options to buy @ $2.99, valued at $149.5k
10/04/2023 4 Kaseta Michael (Director) has filed a Form 4 on ALIMERA SCIENCES INC
Txns: Granted 50,000 options to buy @ $2.99, valued at $149.5k
10/04/2023 4 EISWIRTH RICHARD S JR (President and CEO) has filed a Form 4 on ALIMERA SCIENCES INC
Txns: Granted 400,000 shares @ $0
Granted 400,000 options to buy @ $2.99, valued at $1.2M
10/03/2023 8-K Appointed COO
Docs: "Deadline”). The Release Deadline will in no event be later than fifty days after Executive’s Separation. If Executive fails to return the executed Release on or before the Release Deadline, or if Executive revokes the Release within seven days after return of the executed Release, then Executive will not be entitled to the benefits described in this Section 5. Termination by Board without Cause or by Executive for Good Reason Not in Connection with Change in Control. If the Board terminates Executive’s employment without Cause or Executive resigns for Good Reason and a Separation occurs either more than three months prior to a Change in Control or more than 18 months after a Change in Control, the Company shall pay Executive his earned but unpaid base salary plus 100% of the sum of ...",
"Alimera Sciences Appoints Jason Werner as Chief Operating Officer"
08/23/2023 SC 13G Altium Capital Management LP reports a 5.7% stake in Alimera Sciences, Inc
08/17/2023 4 Morgan Adam (10% Owner) has filed a Form 4 on ALIMERA SCIENCES INC
Txns: Converted 4,845,392 shares @ $1.7, valued at $8.2M
Converted 2,924,762 shares @ $2.1, valued at $6.1M
Converted 4,178,725 shares @ $1.7, valued at $7.1M
Converted 8,117 options to buy @ $0
Converted 7,000 options to buy @ $0
Converted 6,000 options to buy @ $0
08/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/16/2023 SC 13D/A Velan Capital Investment Management LP reports a 26% stake in Alimera Sciences, Inc.
08/15/2023 8-K Unregistered Sales of Equity Securities, Material Modifications to Rights of Security Holders, Changes in Control of Registra...
Docs: "CERTIFICATE OF ELIMINATION OF SERIES B CONVERTIBLE PREFERRED STOCK, PAR VALUE $0.01 PER SHARE, OF ALIMERA SCIENCES, INC. Pursuant to Section 151 of the Delaware General Corporation Law"
08/14/2023 SC 13G LYTTON LAURENCE W reports a 5.7% stake in Alimera Sciences, Inc.
08/11/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/11/2023 3 Caligan Partners LP (10% Owner) has filed a Form 3 on ALIMERA SCIENCES INC
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 SC 13G Stonepine Capital Management, LLC reports a 10% stake in Alimera Sciences, Inc.
08/10/2023 SC 13G BOOTHBAY FUND MANAGEMENT, LLC reports a 9% stake in Alimera Sciences, Inc.
08/10/2023 8-K Quarterly results
Docs: "RECONCILIATION OF GAAP NET PRODUCT REVENUE TO NON-GAAP ADJUSTED NET PRODUCT REVENUE Three Months Ended Six Months Ended June 30, June 30, 2023 2022 2023 2022 GAAP NET PRODUCT REVENUE $ 17,538 $ 14,604 $ 31,084 $ 26,502 Adjustment to net product revenue: Foreign currency fluctuations, net 136 — — NON-GAAP ADJUSTED NET PRODUCT REVENUE $ 17,674 $ 14,604 $ 30,947 $"
08/03/2023 SC 13D/A Caligan Partners LP reports a 33.1% stake in Alimera Sciences, Inc.
08/03/2023 4 Myers C. Daniel (Chairman Emeritus) has filed a Form 4 on ALIMERA SCIENCES INC
Txns: Granted 6,000 options to buy @ $3.26, valued at $19.6k
08/03/2023 3 DeMont Ross D (Director) has filed a Form 3 on ALIMERA SCIENCES INC
08/03/2023 SC 13D/A Velan Capital Investment Management LP reports a 26% stake in Alimera Sciences, Inc.
08/02/2023 8-K Unregistered Sales of Equity Securities, Material Modifications to Rights of Security Holders, Departure of Directors or Cert...
Docs: "ALIMERA SCIENCES, INC. CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF DESIGNATION OF SERIES b CONVERTIBLE PREFERRED STOCK",
"Alimera Sciences, Inc. PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK",
"Appendix A Performance Criteria The Administrator may establish Performance Goals derived from one or more of the following criteria when it makes Awards of Restricted Shares or Restricted Stock Units that vest entirely or in part on the basis of performance or when it makes Performance Cash Awards: · Earnings · Sales or revenue · Earnings per share · Expense or cost reduction · Earnings before interest, taxes and depreciation · Working capital · Earnings before interest, taxes, depreciation and amortization · Economic value added · Total stockholder return · Market share · Return on equity or average stockholders’ equity · Cash measures including cash flow and cash balance · Return on assets, investment or capital employed &...",
"CHAIRMAN EMERITUS AGREEMENT"
08/01/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
07/13/2023 EFFECT Form EFFECT - Notice of Effectiveness:
07/12/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
06/30/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
06/29/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
06/29/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/09/2023 8-K Other Events  Interactive Data
05/31/2023 D/A Form D/A - Notice of Exempt Offering of Securities: [Amend]
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy